Acetaminophen With Codeine
Brand names: Acetaminophen-Codeine
At a glance
- Medicare prescriptions, 2024
- 1,701,430
- Medicare drug cost
- $26.4M
- Average cost per prescription
- $15.53
- Clinicians who prescribed it
- 51,814
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Hydrocodone Bitartrate and Acetaminophen Tablets, USP are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy,, reserve opioid analgesics, including hydrocodone bitartrate and acetaminophen tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of hydrocodone bitartrate and acetaminophen tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of hydrocodone bitartrate and acetaminophen tablets are essential. Accidental Ingestion Accidental ingestion of even one dose of…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 21.3%
- Internal Medicine 15.8%
- Nurse Practitioners 15.2%
- Pain Medicine 9.1%
- Physician Assistants 7.9%
- Dentists (general) 7.8%
- Oral & Maxillofacial Surgeons 3.3%
- Orthopedic Surgery 2.3%
- Physical Medicine & Rehabilitation (PM&R) 1.8%
- Rheumatology 1.7%
- Emergency Medicine 1.6%
- Periodontists 1.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 28% from 2019 to 2024.
Biggest change by state since 2019
- Georgia −3%
- Oklahoma −10%
- Arizona −10%
- Hawaii −11%
- West Virginia −13%
- Rhode Island (smallest change) −55%
- District of Columbia (smallest change) −47%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Pharmpak, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg / 300 mg acetaminophen | white round tablet, 10 mm, scored to split in 2 | 2064 V 3 |
Rhodes Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg / 325 mg acetaminophen | white oval tablet, 15 mm, scored to split in 2 | R P H5 325 |
| 7.5 mg / 325 mg acetaminophen | white oval tablet, 13 mm, scored to split in 2 | R P H7 5 325 |
| 10 mg / 325 mg acetaminophen | white oval tablet, 14 mm, scored to split in 2 | R P H10 325 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Nov 2021 · Ascent Pharmaceuticals, Inc. · Class II
Product Mix-up
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.